Use este identificador para citar ou linkar para este item:
http://hdl.handle.net/1843/76034| Tipo: | Artigo de Periódico |
| Título: | Nicorandil inhibits mechanical allodynia induced by paclitaxel by activating opioidergic and serotonergic mechanisms |
| Autor(es): | Marcela Ísis Morais Márcio de Matos Coelho Renes de Resende Machado Felipe Fernandes Rodrigues Sarah Olivia Alves Mendes da Costa Franciele Aparecida Goulart Fabio Campos Costa Ivo Souza Ferraz de Melo Paulo Sérgio de Almeida Augusto Marcela de Moura Garcia Bini Dutra Ângelo de Fátima |
| Resumo: | Recently, we demonstrated that nicorandil exhibits activities in models of inflammatory and nociceptive pain. In the present study, we extended this investigation by evaluating the effects of nicorandil in models of neuropathic pain induced by paclitaxel or nerve injury in mice. Four intraperitoneal (i.p.) injections of paclitaxel (2 mg/kg.day, cumulative dose 8 mg/kg) or chronic constriction injury (CCI) of the sciatic nerve induced a long lasting mechanical allodynia. Per os (p.o.) administration of two doses of nicorandil (50, 100 and 150 mg/kg) on the 14th day after the first paclitaxel injection attenuated the mechanical allodynia. Equimolar doses of nicotinamide (86.7 mg/kg, p.o.) or nicotinic acid (87.7 mg/kg, p.o.) were devoid of effect. Mechanical allodynia induced by CCI was also attenuated by p.o. administration of two doses of nicorandil (150 mg/kg) on the 14th day after nerve injury. Nicorandil (50, 100 and 150 mg/kg, p.o.) did not affect motor activity. The antinociceptive activity of nicorandil in the model of mechanical allodynia induced by paclitaxel was partially attenuated by naltrexone (5 and 10 mg/kg, i.p.) or cyproheptadine (5 and 10 mg/kg, i.p.), but not by glibenclamide (20 and 40 mg/kg, p.o.). Concluding, nicorandil exhibits activity in experimental models of neuropathic pain when mechanical allodynia is fully established. Activation of opioidergic and serotonergic pathways mediates the antinociceptive activity of nicorandil. It is unlikely that this activity requires biotransformation to nicotinamide or nicotinic acid. Nicorandil should be further evaluated aiming to identify a new alternative in the pharmacological management of neuropathic pain. |
| Assunto: | Dor Farmacologia Dor neuropática Nicorandil Paclitaxel Ácido nicotínico Doxorrubicina Nicotinamida |
| Idioma: | eng |
| País: | Brasil |
| Editor: | Universidade Federal de Minas Gerais |
| Sigla da Instituição: | UFMG |
| Departamento: | FAR - DEPARTAMENTO DE PRODUTOS FARMACÊUTICOS ICX - DEPARTAMENTO DE QUÍMICA |
| Tipo de Acesso: | Acesso Restrito |
| Identificador DOI: | https://doi.org/10.1016/j.ejphar.2018.02.014 |
| URI: | http://hdl.handle.net/1843/76034 |
| Data do documento: | 2018 |
| metadata.dc.url.externa: | https://www.sciencedirect.com/science/article/pii/S001429991830089X |
| metadata.dc.relation.ispartof: | European Journal of Pharmacology |
| Aparece nas coleções: | Artigo de Periódico |
Arquivos associados a este item:
Não existem arquivos associados a este item.
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.